Bioventus Inc.
BVS
$8.62
$0.111.23%
NASDAQ
| 03/28/2026 | 12/31/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.63% | 2.77% | -0.23% | -2.35% | -4.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.63% | 2.77% | -0.23% | -2.35% | -4.31% |
| Cost of Revenue | 1.22% | -3.66% | -2.18% | -4.22% | -0.63% |
| Gross Profit | 9.29% | 5.97% | 0.72% | -1.49% | -6.02% |
| SG&A Expenses | 6.57% | -4.65% | -3.42% | -6.02% | -6.72% |
| Depreciation & Amortization | -30.51% | -26.64% | -32.30% | -30.28% | -9.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.61% | -4.65% | -4.04% | -6.33% | -4.29% |
| Operating Income | 78.75% | 100.65% | 81.37% | 39.27% | -4.79% |
| Income Before Tax | 232.19% | 26,784.91% | 188.80% | 124.82% | 37.58% |
| Income Tax Expenses | 701.05% | -677.27% | 12.73% | 114.18% | -110.47% |
| Earnings from Continuing Operations | 218.78% | 2,971.97% | 168.50% | 127.10% | 47.94% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -221.61% | -1,292.09% | -224.60% | -121.24% | -54.06% |
| Net Income | 218.05% | 3,902.84% | 161.08% | 129.04% | 46.07% |
| EBIT | 78.75% | 100.65% | 81.37% | 39.27% | -4.79% |
| EBITDA | 19.34% | 73.27% | 22.62% | 15.76% | -1.00% |
| EPS Basic | 216.04% | 3,832.20% | 159.54% | 127.99% | 48.32% |
| Normalized Basic EPS | 261.90% | 251.23% | 322.88% | -57.33% | 23.64% |
| EPS Diluted | 200.00% | 3,645.76% | 158.88% | 127.44% | 48.19% |
| Normalized Diluted EPS | 255.24% | 239.88% | 316.34% | -58.62% | 23.64% |
| Average Basic Shares Outstanding | 1.95% | 2.39% | 2.55% | 3.81% | 4.15% |
| Average Diluted Shares Outstanding | 6.06% | 5.82% | 5.48% | 6.99% | 4.15% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |